Clinical characteristics of KRAS mutations in NSCLC and their impact on outcomes to first-line chemotherapy

被引：0
|
作者：
Butaney, Mohit
Porter, Jennifer
Lindeman, Neal Ian
Janne, Pasi A.
Rabin, Michael S.
Marcoux, J. Paul
Johnson, Bruce E.
Jackman, David Michael
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7588
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Impact of Concurrent Tumor Suppressor Gene Mutation on Clinical Outcomes in EGFR Mutated NSCLC Treated with First-Line TKI
    Sharma, S.
    Lee, C.
    Miao, E.
    Seetharamu, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S808 - S809
  • [22] Imact of KRAS mutation on clinical outcomes in pancreatic cancer patients who were treated with first-line gemcitabine-based chemotherapy
    Park, Joon Oh
    Kim, Seung Tae
    Lim, Do Hyoung
    Lee, Jeeyun
    Jang, Kee-Taek
    Choi, Yoon-La
    Jang, Hey-Lim
    Park, Se Hoon
    Park, Young Suk
    Lim, Ho Ho
    Kang, Won Ki
    CANCER RESEARCH, 2011, 71
  • [23] TARGETED THERAPIES Optimal first-line therapy for NSCLC with EGFR mutations
    Neal, Joel W.
    Sequist, Lecia V.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (02) : 70 - 71
  • [24] KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy
    Sharma, Neelesh
    Saifo, Maher
    Tamaskar, Ila R.
    Bhuvaneswari, Ramkumar
    Mashtare, Terry
    Fakih, Marwan
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2010, 1 (02) : 90 - 96
  • [25] Effectiveness of docetaxel and cisplatin combination as first-line chemotherapy in advanced NSCLC
    Behera, D
    Aggarwal, A
    Gupta, D
    Jindal, S
    Aggarwal, R
    Sharma, S
    Kapoor, R
    LUNG CANCER, 2005, 49 : S389 - S389
  • [26] First-line HDACi plus tislelizumab combined with chemotherapy in advanced NSCLC
    Wang, Lijie
    Gao, Ming
    Yang, Wenyu
    Wang, Chunyu
    Wang, Ting
    Jing, Fangfang
    Ma, Junxun
    Zhang, Fan
    Tao, Haitao
    Hu, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] First-line chemotherapy
    Kaye, S
    KEY ADVANCES IN THE CLINICAL MANAGEMENT OF OVARIAN CANCER, 2003, : 33 - 37
  • [28] First-Line Atezolizumab Plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program
    Jotte, Robert M.
    Socinski, Mark A.
    Reck, Martin
    Papadimitrakopoulou, Vassiliki
    West, Howard J.
    Mok, Tony
    Sandler, Alan
    Mocci, Simonetta
    Coleman, Shelley
    Asakawa, Takashi
    Cappuzzo, Federico
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S302 - S303
  • [29] First-Line Atezolizumab plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program
    Cappuzzo, Frederico
    Reck, Martin
    Papadimitrakopoulou, Vassiliki
    Jotte, Robert
    West, Howard
    Mok, Tony
    Sandler, Alan
    Mocci, Simonetta
    Coleman, Shelley
    Asakawa, Takashi
    Socinski, Mark
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1296 - S1297
  • [30] Impact of Baseline Clinical Biomarkers on Treatment Outcomes in Patients With Advanced NSCLC Receiving First-line Pembrolizumab-Based Therapy
    Joshi, Ishani
    Peravali, Monica
    Geng, Xue
    Rao, Suman
    Chen, Kevin Y.
    Veytsman, Irina
    Giaccone, Giuseppe
    Liu, Stephen, V
    Kim, Chul
    CLINICAL LUNG CANCER, 2022, 23 (05) : 438 - 445
12345